Skip to main content

Table 3 Predictors of subsequent treatment for non-transplant and transplant patients with NDMM

From: Frontline treatment patterns and attrition rates by subsequent lines of therapy in patients with newly diagnosed multiple myeloma

 

Non-transplant patients

Overall (N = 22,062)

6+ months follow-upa (n = 14,866)

12+ months follow-upa (n = 11,619)

24+ months follow-upa (n = 7233)

Predictors of subsequent treatment (receiving LOT2+ vs. only LOT1)

Odds ratiob (95% CI)

P-valueb

Odds ratiob (95% CI)

P-valueb

Odds ratiob (95% CI)

P-valueb

Odds ratiob (95% CI)

P-valueb

Age at MM diagnosis, years

 < 65

0.90 (0.84–0.97)

0.0035

1.01 (0.92–1.11)

0.7975

1.09 (0.98–1.22)

0.1154

1.08 (0.94–1.25)

0.2889

 65–74

Reference

Reference

Reference

Reference

 75–84

0.86 (0.80–0.91)

< 0.0001

0.84 (0.77–0.90)

< 0.0001

0.86 (0.78–0.94)

0.0010

0.91 (0.80–1.03)

0.1173

 ≥ 85

0.47 (0.42–0.53)

< 0.0001

0.45 (0.40–0.52)

< 0.0001

0.44 (0.38–0.52)

< 0.0001

0.55 (0.44–0.69)

< 0.0001

Sex, male

0.96 (0.91–1.01)

0.1494

1.03 (0.96–1.10)

0.3843

1.08 (1.00–1.17)

0.0509

1.10 (0.99–1.22)

0.0871

Comorbidities during 180 days prior to index MM diagnosis

 Cardiovascular disordersc

0.84 (0.79–0.90)

< 0.0001

0.84 (0.78–0.91)

< 0.0001

0.83 (0.76–0.91)

< 0.0001

0.88 (0.78–1.00)

0.0479

 Liver disease

0.91 (0.80–1.04)

0.1573

0.88 (0.75–1.03)

0.1195

0.88 (0.72–1.06)

0.1784

0.73 (0.57–0.94)

0.0149

 Pulmonary circulation disorders

0.75 (0.66–0.86)

< 0.0001

0.76 (0.64–0.89)

0.0009

0.75 (0.62–0.91)

0.0030

0.79 (0.60–1.04)

0.0924

 Renal impairment

0.91 (0.85–0.98)

0.0112

0.91 (0.83–0.99)

0.0225

0.97 (0.88–1.07)

0.5209

0.94 (0.82–1.07)

0.3363

 

Transplant patients

Overall (N = 2763)

6+ months follow-upa (n = 2595)

12+ months follow-upa (n = 2245)

24+ months follow-upa (n = 1535)

Predictors of subsequent treatment (receiving LOT2+ vs. only LOT1)

Odds ratiob (95% CI)

P-valueb

Odds ratiob (95% CI)

P-valueb

Odds ratiob (95% CI)

P-valueb

Odds ratiob (95% CI)

P-valueb

Age at MM diagnosis, years

 < 65

1.05 (0.87–1.27)

0.5989

1.13 (0.92–1.38)

0.2421

1.30 (1.03–1.65)

0.0288

1.40 (1.02–1.91)

0.0380

 65–74

Reference

Reference

Reference

Reference

 75–84

1.21 (0.69–2.12)

0.5059

1.00 (0.57–1.77)

0.9953

1.11 (0.55–2.23)

0.7656

0.75 (0.34–1.67)

0.4855

 ≥ 85

Sex, male

1.20 (1.00–1.44)

0.0543

1.18 (0.97–1.45)

0.1029

1.18 (0.93–1.49)

0.1650

1.27 (0.94–1.73)

0.1218

Comorbidities during 180 days prior to index MM diagnosis

 Cardiovascular disordersc

0.85 (0.68–1.08)

0.1790

0.86 (0.67–1.11)

0.2423

0.88 (0.66–1.17)

0.3664

0.99 (0.68–1.45)

0.9528

 Liver disease

0.56 (0.39–0.81)

0.0017

0.49 (0.34–0.70)

0.0001

0.48 (0.31–0.73)

0.0005

0.41 (0.23–0.72)

0.0020

 Pulmonary circulation disorders

0.70 (0.39–1.27)

0.2466

0.60 (0.33–1.09)

0.0926

0.51 (0.26–1.01)

0.0520

0.36 (0.14–0.90)

0.0281

 Renal impairment

0.79 (0.62–1.02)

0.0668

0.71 (0.54–0.92)

0.0099

0.74 (0.55–1.01)

0.0601

0.58 (0.40–0.86)

0.0059

  1. CI Confidence interval, LOT Line of therapy, MM Multiple myeloma
  2. aMonths of follow-up were calculated from the start of the first line of treatment until either the end of insurance eligibility (for SEER and OPTUM™ Commercial)
  3. bOdds ratios and p-values were computed using a logistic regression
  4. cCardiovascular disorders include cardiac arrythmia, congestive heart failure, complicated hypertension, and valvular disease